Frontier Bio Corp — SEC Form D Filing
Frontier Bio Corp filed an SEC Form D on November 10, 2026, reporting $380K raised in Regenerative Medicine.
Form D filing details
- Filing
- SEC Form D
- Filing date
- November 10, 2026
- Amount reported
- $380K
- Round stage
- Seed
- Industry
- Regenerative Medicine
- Website
- https://www.frontierbio.com/
What the company does
Securities: Simple Agreement for Future Equity (SAFE), convertible into preferred stock. Exemption: Rule 506(b). Incorporated: DELAWARE
Problem
Surgeons needing replacement blood vessels currently rely on synthetic grafts that carry a high risk of clotting, or on harvesting a patient's own veins, which adds surgical time, creates a second wound, and is not an option for patients lacking suitable spare veins.
Solution
Frontier Bio develops living vascular grafts made by seeding a dissolvable scaffold with cells extracted from a patient's fat sample, enabling implantation during the same surgery to regenerate a natural living vessel.
Why now
Advances in bioresorbable materials and intraoperative cell-isolation techniques make it feasible to seed and implant tissue-engineered grafts within a single surgical procedure.
Verdict
This cleared because the clinical misery of synthetic graft failure is undisputed, not because the company proved a point-of-care cellular workflow scales economically. Investors backed the thesis that an intraoperative autologous graft sidesteps the severe immunogenicity and cold-chain distribution baggage weighing down acellular tissue competitors. They were implicitly betting that vascular surgeons would trade operating-room convenience for superior long-term patency. However, the micro-raise ($380,000) signals heavy investor hesitation around surgical friction, regulatory combination-product classification, and the questionable economics of custom, chairside biomanufacturing.
Source: SEC EDGAR Form D filing